We have previously shown that 3A2 treatment confers robust protection against diet-induced obesity and age-associated insulin resistance in mice via inhibition of MT1-MMP activities without the induction of adverse effects25,51, demonstrating the in vivo efficacy of this antibody in targeting MT1-MMP. This evidence concerns the gene MMP14 and obesity due to melanocortin 4 receptor deficiency.